Mesoblast Ltd. is a commercial-stage biotechnology company specializing in the research, development, and commercialization of allogeneic, off-the-shelf cellular medicines. The company's proprietary technology platform utilizes mesenchymal lineage adult stem cells to target complex diseases where inflammation plays a central role and that are resistant to conventional standard of care. Its late-stage product candidates include Ryoncil (remestemcel-L) for steroid-refractory acute graft versus host disease, Revascor (rexlemestrocel-L) for advanced chronic heart failure, and MPC-06-ID for chronic low back pain. Headquartered in Melbourne, Australia, Mesoblast maintains a global footprint with operations and clinical trials spanning the United States, Europe, and Asia. A notable characteristic of its cellular therapies is that they can be administered to patients without the need for donor-recipient matching or recipient immune suppression.
